Inotiv Q3 FY2022 revenue rises to $172.7M; raises FY2022 revenue guidance to at least $550M

Inotiv, Inc.

2022-Q3 EPS reported -$3.88 revenue$397,190,000

Q3 FY2022 revenue $172.7M vs $22.9M a year ago; DSA revenue $49.2M (+114.8% YoY), RMS $123.4M from nil.
Net loss $(3.6)M vs net income $2.6M in Q3 FY2021; adjusted EBITDA $37.0M (21.4% rev) vs $2.2M (9.6%).
Raises FY2022 revenue guidance to at least $550M (from $510M); adjusted EBITDA margin at least 17.0% (from 15.0%).
DSA backlog $143.2M at June 30, 2022, up from $62.0M a year ago; book-to-bill 1.19x.
YTD cash used in ops $5.4M; debt $338.8M; subsequent acquisition of Protypia for large molecule bioanalysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.